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Abstract
Background: The genetic and molecular mechanisms responsible for and associated specifically with the
development and progression of malignant prostate cells are largely unidentified. In addition, despite its
implication in virtually all malignant cells, the role of altered cellular metabolism as an essential factor in
prostate malignancy has been largely ignored. Moreover, the intermediary metabolism of normal prostate
as well as malignant prostate cells is among the least studied and most poorly understood of all mammalian
cells. Some important factors, especially the role of zinc, have been identified and implicated in the
development and progression of prostrate malignancy. In this review, we provide a current and updated
integrated assessment of the relationships of intermediary metabolism in normal prostate and in prostate
cancer. The experimental and clinical evidence that leads to the formulation of concepts of normal and
malignant prostate metabolism is presented. The evidence for a concept of zinc as a tumor suppressor
agent and Zip1 zinc transporter as a tumor-suppressor gene is described.
Results: The specialized function of the normal prostate glandular epithelium to produce and secrete
enormously high levels of citrate involves and requires unique intermediary metabolism activities that are
not generally associated with other normal mammalian cells. The accumulation of zinc by these cells is an
essential factor in this unique metabolic relationship. In malignancy, the normal zinc-accumulating citrate-
producing epithelial cells are metabolically transformed to citrate-oxidizing cells that lose the ability to
accumulate zinc. A genetic alteration in the expression of ZIP1 zinc transporter is associated with this
metabolic transformation. These genetic/metabolic relationships have important consequences on citrate-
related metabolism, bioenergetics, cell proliferation and invasive capabilities of the malignant cells, which
result in tumor-suppression characteristics.
Conclusion: The genetic/metabolic relationships in normal prostate glandular epithelium are driven by
the unique function to accumulate and secrete citrate. The genetic/metabolic transformation of the
prostate malignant cells is driven by the metabolic/bioenergetic, growth/proliferative, and invasive/
migration requirements of the malignant process. Zinc is critical to these relationships. An understanding
of these genetic/metabolic relationships provides new directions and opportunities for development of
regimens for the prevention and treatment of prostate cancer. Important insight into the genetic/
metabolic requirements of the prostate malignant process is now evolving. Most importantly at this time,
an appreciation and recognition of the genetic/metabolic significance and implications in the development
of prostate malignancy is imperative; and much needed research in this area is essential. Hopefully, this
review will help to achieve these goals.
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Introduction
About 230,000 males are expected to be identified with
prostate cancer in the next year that will result in about
30,000 deaths. Despite the extensive clinical and experi-
mental studies over the recent decades, the pathogenesis
of prostate cancer remains unknown. The genetic and
molecular mechanisms responsible for and associated
specifically with the development and progression of
malignant prostate cells are largely unidentified [[1,2] for
reviews]. Coupled with this is the largely ignored role of
altered cellular metabolism as an essential factor in pros-
tate malignancy; although transformations of metabolism
are implicated in virtually all malignant cells [3-8]. The
combination of genetic/molecular/metabolic relation-
ships is required to identify critical events in the prostate
malignancy process. Such studies are beginning to reveal
an essential understanding of the development and pro-
gression of prostate cancer.
This review will provide a current and updated integrated
assessment of the relationships of intermediary metabo-
lism in normal prostate and in prostate cancer. Much of
the description of important contributions of earlier
investigators and early studies that should be recognized
is presented in our previous reviews [8-12]; and will not
be repeated except where relevant to the present discus-
sion. We will describe the experimental and clinical evi-
dence that leads to the formulation of concepts of normal
and malignant prostate metabolism. Important gaps,
unresolved issues, and areas of required future studies
relating to prostate intermediary metabolism will be iden-
tified. The review will culminate in defining important
genetic/metabolic events in the development and progres-
sion of prostate malignancy. The evidence for a concept of
zinc as a tumor suppressor agent and ZIP1  zinc trans-
porter as a tumor-suppressor gene will be described. The
clinical/translational application of these relationships is
also presented.
The totality of this presentation is intended first to be
informative. Hopefully, the presentation will be stimulat-
ing and even provocative; so that more attention is
directed to this subject matter and other investigators
might become involved. Finally, we hope to convince the
clinical and scientific community-at-large of the impor-
tance of metabolic relationships in the development and
progression of prostate cancer, and the relevance to new
approaches to detection, treatment, and perhaps preven-
tion of prostate cancer.
Axioms of relationships of cellular activity, cellular 
metabolism, and malignancy
The following are important generalizations that we con-
sider to be axiomatic.
1). In all cells, the existing cellular intermediary metabo-
lism provides the bioenergetic/synthetic/catabolic
requirements that are essential for the manifestation of
the cells' current activities (function, growth, prolifera-
tion).
2). When a cell's activity changes, its metabolism must
also be adjusted consistent with any newly established
bioenergetic/synthetic/catabolic requirements
3). Malignant cells exhibit a parasitic existence. They have
no specialized function other than the activities essential
for their generational propagation (growth and prolifera-
tion), which occurs at the expense of their host.
4). Malignant cells are derived from normal cells that have
undergone a genetic transformation to a neoplastic cell
phenotype that is endowed with malignant potential.
5). Manifestation of the malignant potential of the neo-
plastic cell necessitates alterations in its metabolism (ie a
metabolic transformation) to provide the bioenergetic/
synthetic requirements of malignancy.
The concept of genetic/metabolic development of malignant cells Figure 1
The concept of genetic/metabolic development of malignant cells.Molecular Cancer 2006, 5:17 http://www.molecular-cancer.com/content/5/1/17
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6). In the absence of the metabolic transformation, the
neoplastic cell will not progress to complete malignancy.
Conversely, the metabolic transformation, in the absence
of the genetic transformation to a neoplastic malignant
cell, will not cause malignancy.
7). Common to all malignant cells is the metabolic
requirement for de novo lipogenesis/cholesterogenesis for
membraneogenesis that is essential for their proliferative
existence.
These axioms define a relationship represented in figure 1
that we propose is applicable to all malignancies.
Normal prostate function and associated intermediary 
metabolism: net citrate production
The human prostate gland is a complex organ comprised
of different zones that have different embryological origin
and different functional activities. The focus of this pres-
entation is the peripheral zone, which comprises about
70% of the gland, and is the major functional component.
Most importantly, this is the major region of malignancy.
The primary function of the prostate gland is the produc-
tion and secretion of prostatic fluid [8-12]. The major
component of the prostatic fluid is its extraordinarily high
concentration of citrate, which ranges from ~40–150 mM
as contrasted with ~0.2 mM citrate in blood plasma (Table
1). Correspondingly, normal peripheral zone tissue citrate
levels range from ~10,000–15,000 nmols/gram as con-
trasted with other tissues that generally contain ~250–450
nmols/gram.
Table 1: REPRESENTATIVE PROSTATE LEVELS
(NMOLS/GRAM WWT) CITRATE ZINC
NORMAL PERIPHERAL ZONE 12,000–14,000 3,000–4,500
MALIGNANT TISSUE 200–2000 400–800
OTHER TISSUES 250–450 200–400
PROSTATIC FLUID 40,000–150,000 8,000–10,000
BLOOD PLASMA 100–200 15
The metabolic pathway and bioenergetics of net citrate production in prostate cells Figure 2
The metabolic pathway and bioenergetics of net citrate production in prostate cells.Molecular Cancer 2006, 5:17 http://www.molecular-cancer.com/content/5/1/17
Page 4 of 13
(page number not for citation purposes)
The function of prostate citrate production is achieved by
the activity of highly specialized glandular epithelial cells
that have evolved for the capability to accumulate and
secrete citrate, which we refer to as "net citrate produc-
tion". This capability does not exist in other mammalian
cells. Consequently the intermediary metabolism of these
"citrate-producing" cells is "driven and modified" by their
specialized function of net citrate production (figure 2).
In typical mammalian cell intermediary metabolism, glu-
cose utilization via glycolysis produces pyruvate which
enters the mitochondria and is oxidized to acetyl coA. The
acetyl coA condenses with OAA to produce citrate which
is oxidized via the Krebs cycle with the regeneration of
OAA. Consequently, in the oxidation of six-carbon citrate,
two carbons are lost (CO2 production) and four carbons
are conserved as OAA. In the citrate-producing prostate
cells, all six carbons are removed from the metabolic pool;
and citrate is an end-product of metabolism, rather than
an utilizable intermediate. Therefore, citrate synthesis in
these cells requires the availability of a source of acetyl
coA and a source of OAA. The former is derived from glu-
cose as described above. The latter is derived from aspar-
tate. One must recognize the magnitude of prostate citrate
production. The production of 1 ml of prostatic fluid, on
average, involves the production of 100 umols citrate. To
achieve this, 50 umols glucose and 100 umols aspartate
will be utilized. The concentration of glucose and aspar-
tate in blood plasma is 5 umols/ml and 0.03 umol/ml,
respectively. Thus, a tremendous demand on the availabil-
ity of glucose and aspartate is required for prostate citrate
production.
To meet the precursor requirements for continued citrate
synthesis, the prostate epithelial cells possess unique glu-
cose and aspartate relationships. These cells, unlike most
other mammalian cells, utilize glucose via a high aerobic
glycolysis [13-17] that provides a high production of lac-
tate←→pyruvate that is available for the production of
acetyl coA.
For the production of OAA, aspartate is accumulated in
the prostate cells and is transaminated via mAAT and cou-
pled to GDH activity in a pathway that we define as the
aspartate-glutamate-citrate pathway (figure 2). In these
cells aspartate is an essential amino acid that is utilized;
which is unlike most other mammalian cells that synthe-
size aspartate as a non-essential amino acid. Because the
plasma aspartate concentration is low (0.03 mM) relative
to its requirement for high citrate production, the prostate
cells maintain a high cellular aspartate concentration (1.2
mM) availability for citrate synthesis [18]. This requires a
capability of the prostate cells to extract and accumulate
aspartate from circulation against the 40:1 concentration
gradient. To achieve this, the prostate cells exhibit a high-
affinity L-aspartate transport process [18-20]. We recently
identified EAAC1 as the high-affinity aspartate transporter
[21]; which is unique since EAAC1 in other mammalian
cells generally operates as a high-affinity glutamate trans-
porter rather than an aspartate transporter.
The relationships described above involve the metabolic
adaptations that are essential to facilitate citrate synthesis.
The accumulation of citrate is dependent upon its rate of
synthesis versus its rate of utilization. The prevention of
citrate oxidation by the prostate cells is the key relation-
ship that is responsible for net citrate production. The
prostate peripheral zone accumulates extremely high lev-
els of zinc in the range of ~3000–5000 nmols/gram as
compared to other tissues being ~200–400 nmols/gram.
The cellular accumulation of zinc results in high levels of
mitochondrial zinc that inhibit m-aconitase activity and
citrate oxidation [22]. That zinc inhibition is the essential
cause of limiting m-aconitase activity is evident from the
recent observation that the level of m-aconitase enzyme is
not low or changed in normal or malignant human and
animal prostate cells [23] The inhibition of m-aconitase
truncates the Krebs cycle at the first step of citrate oxida-
tion; which provides the most efficient metabolic altera-
tion for synthesized citrate to accumulate for secretion
(figure 2).
Net citrate production has significant bioenergetic impli-
cations (figure 2). Compared to citrate-oxidizing cells that
produce 38 ATP/complete oxidation of glucose; the cit-
rate-producing prostate epithelial cells generate 14ATP/
glucose utilized (or 20ATP if the NADH from the GDH
reaction is oxidized by terminal oxidation). To accumu-
late citrate for secretion, these specialized cells sacrifice
~60% of the potential energy that could be derived from
complete oxidation of glucose. In contrast to these highly
specialized prostate cells, most mammalian cells cannot
survive if m-aconitase activity and citrate oxidation are
inhibited as is evident from the toxic effects of the m-aco-
nitase inhibitor, fluorocitrate.
Altered citrate and zinc relationships in prostate cancer: 
the metabolic transformation
It is now well established that citrate and zinc levels are
markedly decreased in malignant versus normal prostate
tissue. These biochemical changes occur early in the devel-
opment of malignancy. Moreover, malignant prostate tis-
sue virtually never retains the characteristic high levels of
citrate and zinc found in normal peripheral zone. In the
absence of high cellular zinc levels, m-aconitase activity is
no longer inhibited and citrate oxidation proceeds via the
Krebs cycle (figure 2). Thus we characterize the metabolic
transformation as the transformation of zinc-accumulat-
ing citrate-oxidizing normal prostate epithelial cells to cit-
rate-oxidizing cells that have lost the ability to accumulate
zinc.Molecular Cancer 2006, 5:17 http://www.molecular-cancer.com/content/5/1/17
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An important benefit of this metabolic transformation is
the bioenergetic relationship in that citrate oxidation pro-
vides the additional 24ATP from complete glucose oxida-
tion that were lost by incomplete glucose oxidation in net
citrate production. Thus, the malignant cells are bioener-
getically more efficient than the specialized normal pros-
tate epithelial cells. This is in contrast to the general tumor
metabolism relationship in which the tumor cells are met-
abolically transformed to high aerobic glycolysis [3-7].
Figure 3 shows our concept of the genetic/metabolic
transformation of the citrate-producing normal epithelial
cell to the citrate-oxidizing malignant cell in the develop-
ment of prostate malignancy.
The metabolic role of citrate: oxidation and/or cytosolic 
acetyl CoA production
In mammalian cells, citrate is synthesized in the mito-
chondria where it is either oxidized via the Krebs cycle or
it is exported to the cytosol (figure 4). In the cytosol, the
citrate is converted by ATP citrate lyase to acetyl coA,
which is then utilized in lipogenesis/cholesterogenesis. In
normal prostate cells, as already described, very little cit-
rate is oxidized; so that essentially all the synthesized cit-
The concept of the role of zinc and altered citrate matabolism in the development of prostate malignancy Figure 3
The concept of the role of zinc and altered citrate matabolism in the development of prostate malignancy.
The pathways of citrate in mammalian cells Figure 4
The pathways of citrate in mammalian cells. Pathway of citrate synthesis shown with black arrows is common to all cells. Path-
way of citrate oxidation via the Krebs cycle is shown with blue arrows. Pathway of citrate export and utilization for lipogenesis/
cholesterogenesis is shown with red arrows. Pathway of citrate secretion that occurs only in normal prostate cells is shown 
with green arrow.Molecular Cancer 2006, 5:17 http://www.molecular-cancer.com/content/5/1/17
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rate is destined for export to cytosol. The cytosolic citrate
is then secreted into prostate fluid. This leads to the expec-
tation that ATP citrate lyase activity must be absent or very
low in these prostate cells due to the absence of the
enzyme or the existence of an inhibitor of the enzyme.
Currently, reports concerning this relationship in normal
prostate cells do not exist. Halliday et al [24] did infer that
ATP citrate lyase activity was low in benign prostate glands
and increased in malignant prostate glands; but direct
studies of the enzyme were not conducted.
This requires another metabolic adaptation for the spe-
cialized function of citrate secretion. As shown in figure 4,
the export of citrate is coupled to the import of a counter-
ion, which is usually malate. The counter-ion is generated
from the ATP citrate lyase production of OAA, which is
absent in the normal citrate-producing prostate cell.
Therefore, these cells must have an alternative source (cur-
rently unidentified) of a counter-ion for the export of cit-
rate into the cytosol.
As already described, the malignant prostate cells undergo
a metabolic transformation to citrate oxidation. However,
for the malignant cells to proliferate they must also adapt
their metabolism for the utilization of citrate for de novo
lipid biosynthesis. The initiating steps in this pathway are
the export of citrate into cytosol followed by its conver-
sion to acetyl coA. Therefore, an essential metabolic adap-
tation in the malignant prostate cells must be an increase
in ATP citrate lyase activity. Halliday et al [24] observed
that a decrease in citrate levels correlates with a corre-
sponding increase fatty acid levels in prostate malignant
glands as contrasted with no such changes in neighboring
BPH glands. They concluded that this is indicative of an
increase in ATP citrate lyase activity in malignancy. Swin-
nen et al [25] present an informative review of existing
evidence that the expression and levels of some important
lipogenic/cholesterogenic enzymes are upregulated in
malignant prostate cells. It is of particular interest that FAS
levels are increased in PIN and more so in the adenocarci-
nomatous glands, which is consistent with the metabolic
transformation occurrence early in malignancy. It is
apparent that the development and progression of pros-
tate malignancy involves a metabolic shift to de novo
lipid biosynthesis.
The available evidence indicates that, in prostate malig-
nant cells, the mitochondrial citrate pool is utilized for
oxidation via the Krebs cycle and for export to cytosol for
utilization in de novo lipid biosynthesis. This is in con-
trast to the prevailing concept of tumor cell metabolism of
a "truncated Krebs cycle" as proposed by Parlo and Cole-
man [26,27]. The concept proposes that an increased cit-
rate shuttle activity causes rapid export of citrate; thereby
depleting citrate for oxidation by the Krebs cycle. It is well
documented that the Krebs cycle downstream reactions
from isocitrate to oxalacetate are operational in tumor
cells [26-31]. However, the critical reaction is m-aconi-
tase, about which little is known in tumor cells. Kelleher
et al [30] and Dietzen and Davis [31] reported the exist-
ence of a complete Krebs cycle including citrate oxidation
in hepatoma cells. In contrast, Hernanz and de la Fuente
[32] reported that the Krebs cycle is truncated in
hepatoma cells and concluded that m-aconitase activity
was impaired. However, in the presence of m-aconitase
activity and isocitrate oxidation, it is not possible that the
rate of citrate export could deplete citrate so that essen-
tially no citrate oxidation would occur. The kinetic rela-
tionships of citrate export versus m-aconitase activity
dictate that, in the presence of a sufficient intramito-
chondial pool of citrate that would support high citrate
export, m-aconitase activity and citrate oxidation will pre-
vail. Therefore, in prostate malignant cells, and likely in
other tumor cells, citrate oxidation and citrate export can
co-exist as long as sufficient precursors are available for
citrate synthesis.
The above description presumes that citrate is the essen-
tial source of cytosolic acetyl coA for de novo lipogenesis/
cholesterogenesis in malignant prostate cells. However,
the possibility exists that acetate derived from circulation
might be an alternative precursor for acetyl coA produc-
tion. This would require the existence of cytosolic acetyl
coenzyme A synthetase (AceCS1), which is up-regulated
in some lipogenic mammalian cells [33-35]. It is of inter-
est that Pomare et al [36] observed a highly significant
~50% decrease in arterial plasma acetate levels of cancer
subjects compared to normal subjects, which suggests that
malignant cells might be utilizing acetate from circula-
tion. Hatzivassiliou et al [37] reported the expression of
AceCS1 in some malignant cell lines as well as the utiliza-
tion of acetate. They also showed that inhibition of ATP
citrate lyase resulted in >90% inhibition of A549
xenograft tumor growth, but only about 50% inhibition
of PC-3 tumor growth; which could be indicative of PC-3
tumor cell utilization of acetate for AcCoA synthesis. Our
recent studies (unpublished information) show that
AceCS1 is expressed in PC-3 cells in culture and in PC-3
xenograft tumor cells. Therefore the possible utilization of
acetate as a supplemental or alternative source of acetyl
coA for lipogenesis/cholesterogenesis in prostate nalig-
nancy must be investigated.
Citrate in the detection of prostate cancer- Magnetic 
Resonance Spectroscopy Imaging (MRSI)
The following presents a significant translational clinical
application of the citrate metabolic relationship. A major
current problem involved in prostate cancer (PCa) is the
absence of sensitive, accurate, and preferably non-invasive
procedures for the diagnosis of PCa. Moreover proceduresMolecular Cancer 2006, 5:17 http://www.molecular-cancer.com/content/5/1/17
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are needed that will permit the early detection, staging,
location, and estimation of the volume of the malignancy;
and preferably a mapping of the prostate for follow-up of
progression and regression of the malignancy. The unique
citrate metabolism relationships of the prostate, coupled
with recent developments and technological advance-
ments in 1-H MRSI for the in situ determination of citrate
levels, provides an excellent diagnostic/detection proce-
dure which can achieve all these goals. In addition, the
mapping of malignant loci permits accurate and precise
MRSI guided radiotherapy and chemical seeding in target-
ing and concentrating the treatment at the malignant tis-
sue. There now exist strong, compelling basic and clinical
studies in support of the employment of MRS measure-
ments of citrate and other associated metabolites in the
diagnosis of PCa and in the in situ visualization of malig-
nant loci [[38-40]; for reviews].
The combination of magnetic resonance imaging (MRI)
and MRSI results in a metabolic-anatomic visualization
(ie a metabolic map) of the prostate gland. Figure 5 shows
the in situ metabolic profile of a normal prostate gland;
and also reveals, as we proposed in 1991 [41], that the
peripheral zone is the specific region of the prostate that
is responsible for the function of citrate production and
secretion. In contrast to the uniformly high citrate in nor-
mal peripheral zone tissue, the presence of malignant loci
exhibits a depletion of citrate. Conversely, the choline and
creatine levels are low in normal peripheral zone, and
increase in malignant loci. It is likely that the choline
increase is due to the requirement for increased mem-
braneogenesis that is essential for growth/proliferation of
the malignant cells. This inverse relationship is com-
monly employed as a ratio for identifying malignant sites
in the peripheral zone. MRSI also reveals that glandular
BPH involves the proliferation of citrate-producing secre-
tory epithelial cells, presumably from transition zone,
into the central zone (figure 5).
Figure 6 is a composite of early studies from three differ-
ent laboratories that employed 1-H MRS examination of
patient populations [42-44]. The results reflect the strik-
ing consistency of the significant decrease in peripheral
zone citrate levels of PCa versus normal or BPH prostate.
It is notable that none of the PCa subjects from the three
separate studies exhibited peripheral zone malignancy
that exhibited a high citrate level representative of the nor-
mal peripheral zone citrate level. This provides evidence
that malignant prostate cells in situ do not exist as citrate-
producing cells. This supports the concept that the meta-
bolic transformation is essential for the manifestation of
malignant activities of the neoplastic cells.
In situ magnetic resonance spectroscopy imaging of prostate gland Figure 5
In situ magnetic resonance spectroscopy imaging of prostate gland. Adapted from Kurhanewicz et al [42].Molecular Cancer 2006, 5:17 http://www.molecular-cancer.com/content/5/1/17
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Zinc: a tumor suppressor agent in prostate cancer?
Any suggestion of tumor suppression in prostate cancer by
an agent and/or a gene must have a strong and rational
clinical as well as experimental basis. The following enu-
merates the supporting information regarding zinc sup-
pression of prostate malignancy. As already emphasized,
malignant prostate tissue is characterized by a dramatic
decrease in zinc level as compared to extremely high zinc
levels in normal and hyperplastic glands. Most impor-
tantly, malignant tissue rarely, if ever, exhibits the high
zinc content that characterizes nonmalignant prostate
glands. The consistency of these relationships is further
represented in Table 2 that summarizes the results of sev-
enteen separate reports in which zinc levels were com-
pared for normal prostate, BPH, and cancer tissue
samples. The studies represent a diversity of tissue collec-
tion procedures, a diversity of subjects and clinical condi-
tions, a diversity of zinc analytical methods and
calculations, and other such variables. Despites such het-
erogeneous conditions, a consistent 68% decrease with
only a 3% standard error is evident. In contrast, while
BPH shows a trend toward an 65% increase in zinc versus
normal prostate, the standard error is about 100%; ie a
high variability. Figure 7 derived from Zaichick et al [45]
shows individual zinc values in prostate tissues obtained
from different subjects. The zinc levels in cancer tissue are
decreased by ~85% compared to normal tissue values.
Most importantly, there is no cancer sample that contains
the high zinc levels that characterize normal or BPH levels
(i.e. no overlap of the mean +/- sem). It is also significant
that the distribution of zinc levels in figure 7 mirrors the
observations of citrate changes shown in figure 6. Due to
the fact that the decrease in citrate is due to and preceded
by the depletion of zinc, the in situ MRS studies are also
indirect measurements of changes in zinc in malignancy.
All of this evidence is culminated in the in situ study that
shows the depletion of zinc in adenocarcinomatous
glands as contrasted with accumulated zinc in the glandu-
lar epithelium of normal peripheral zone glands [46].
This study also dispels the notion that the decrease in zinc
in prostate cancer tissue is due to a decrease in luminal
prostatic fluid rather than a decrease in cellular zinc. We
submit that all of these observations in combination
firmly establish that normal prostate glandular epithe-
Table 2: ZINC LEVELS IN PROSTATE COMPILED FROM 17 
PUBLISHED REPORTS
MEAN VALUES % CHANGE FROM
NORMAL
MEAN +/- SEM MEAN (SEM)
NORMAL 755 +/- 158 ---------------------
BPH 1270 +/- 273 +65 (45)% NS
PCA 276 +/- 48 -68 (3)% P<0.001
% CHANGE FROM NORMAL IS OBTAINED FROM THE 
SUM OF THE CHANGES OBSERVED IN EACH STUDY 
THAT INCLUDED NORMAL VALUES (15 REPORTS)
Compilation of in situ MRS citrate analysis of prostate glands from three studies Figure 6
Compilation of in situ MRS citrate analysis of prostate glands from three studies. PZ = peripheral zone; CZ = central zone.Molecular Cancer 2006, 5:17 http://www.molecular-cancer.com/content/5/1/17
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lium accumulates high zinc levels; and, conversely, the
malignant cells lose the ability to accumulate zinc early in
the malignant process.
The inability of malignant cells to accumulate zinc is not,
in itself, evidence of a tumor-suppressive effect of zinc.
There must be associated effects and consequences of zinc
that are inhibitory to the malignant cells. Such anti-tumor
consequences do exist and can be characterized as follows.
a. Metabolic/bioenergetic effects. As already described,
zinc accumulation in prostate cells truncates the Krebs
cycle and inhibits citrate oxidation. In addition, high zinc
levels also inhibit the respiration and terminal oxidation
of prostate mitochondria [47]. These metabolic effects of
zinc have bioenergetic and synthetic consequences as
already discussed.
b. Growth/proliferation effects. The accumulation of zinc
inhibits growth and proliferation of prostate cells [48].
We reported [49,50] that zinc induces apoptogenesis in
prostate cells that results from its direct effect on mito-
chondrial release of cytochrome c followed by activation
of the caspase cascade and ultimately apoptosis. This
effect is corroborated by the recent report of Huang et al
[51]. Uzzo et al [52] reported that zinc sensitized malig-
nant prostate cells to apoptosis through its inhibition of
NF-kB.
c. Invasive/migration effects. Zinc has also been shown to
inhibit the invasive capabilities of malignant prostate
cells. Ishii et al. [53] reported that the ability of LNCaP
cells to invade Matrigel was strongly suppressed by Zn++.
In another study Ishii et al. [54] found that aminopepti-
dase N purified from human prostate was irreversibly
inhibited by low concentrations of zinc; which, they con-
cluded, could be associated with invasive capability. Uzzo
et al [55] reported that the suppressive effect of zinc on the
angiogenic and metastatic potentials of cancer cells was
also mediated through the inhibition of specific pathways
that regulate progression of prostate cancer.
These effects of zinc accumulation are inhibitory to and
incompatible with the prostate malignant process and can
be defined as "tumor suppressor" effects of zinc. The
depletion of zinc that occurs in malignant prostate cells in
situ eliminates these anti-tumor effects. Under these con-
ditions the neoplastic cell is able to meet the metabolic/
bioenergetic requirements of malignancy, is able to grow
and proliferate, and is able to invade the host tissue and
metastasize.
Zip1: a tumor suppressor gene in prostate cancer?
The critical issue becomes the mechanism involved in the
unique ability of normal prostate cells to accumulate high
zinc levels; and the mechanism involved in the lost ability
of malignant cells to accumulate zinc. For an extensive
review of zinc and zinc transporters in prostate cells see
[9]. The intracellular level of all cells is firstly dependent
upon the existence of zinc uptake transporters to extract
zinc from external (e.g. interstitial fluid) sources. Once
within the cell, the cellular zinc might be subjected to zinc
export from the cell. Until recently, virtually no informa-
tion existed regarding the mechanisms/processes involved
in the accumulation of zinc in prostate cells. Because zinc
uptake is the first step in the cellular accumulation of zinc,
we had initiated studies to identify this process in prostate
cells; and demonstrated that prostate cells contain a rapid
zinc-uptake transport process that is operational at low
concentrations of zinc representative of plasma zinc levels
[56]. We tentatively identified hZIP1 as the zinc uptake
transporter associated with this transport process. In pur-
suant studies, Franklin et al [57] functionally established
hZIP1 as the transporter that functions in the uptake and
accumulation of zinc in prostate cells. This role of ZIP1 in
prostate cells was corroborated by others [51,58].
However, all of the above studies were conducted in pros-
tate culture cells under in vitro conditions. An essential
missing link was the relationship in normal and malig-
nant prostate glands in situ. The first clue was derived
from the report of Rishii et al [59] who found that ZIP1
expression (determined by RT-in situ-PCR) in prostate
glandular epithelium was low in African-American males
as compared to Caucasian males. They concluded that this
genetic racial difference could account for the higher sus-
ceptibility of African-Americans to prostate cancer. In a
recent study, the in situ expression and levels of ZIP1 and
zinc in malignant versus nonmalignant prostate glands in
tissues from prostate cancer subjects were determined
[46]. The results demonstrated the consistent down regu-
lation of ZIP1 gene expression, the decrease in ZIP1 trans-
porter protein, and the depletion of cellular zinc levels in
malignant versus nonmalignant glands. Thus, the clinical
and experimental evidence are corroborative of the role of
ZIP1 and zinc changes associated with the transformation
of normal glandular epithelial cells to malignant cells.
Consequently, as long as ZIP1 transport activity exists and
results in high zinc accumulation, the tumor suppressor
effects of zinc will prevent the malignant activities of the
neoplastic cells. Therefore, we propose that ZIP1
(SLC39A1) can be described as a tumor suppressor gene
in prostate cancer.
This leads to the issue of the mechanism of down regula-
tion of ZIP1 expression in the neoplastic/malignant cell in
situ. In contrast to its down-regulation in the malignant
prostate glands in situ, Zip1 is expressed in human pros-
tate malignant and nonmalignant cell lines thus far exam-
ined [46,51,56-58]. No information currently existsMolecular Cancer 2006, 5:17 http://www.molecular-cancer.com/content/5/1/17
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regarding its expression in metastatic sites in situ. The
reappearance of ZIP1 in the cell lines demonstrates the
likelihood that its down-regulation in adenocarcinoma-
tous glands is not due to a permanent fatal mutation or
gene deletion; but probably results from epigenetic silenc-
ing of gene expression under in situ conditions. Conse-
quently, our proposal that ZIP1  is a tumor suppressor
gene in prostate cancer is similar to the reported involve-
ment of SLC5A8 as a tumor suppressor gene in colon and
other cancers [60-65]. SLC5A8 encodes a monocarboxylic
acid transporter protein, and its down regulation results
from epigenetic silencing. The specific role of the trans-
porter in tumor suppression is not established. Ganapathy
et al [62] propose that the monocarboxylic acid trans-
porter causes the accumulation of butyrate, which has an
apoptotic effect that is inhibitory in a variety of tumor
cells. As we described, the role of ZIP1 transporter and
zinc accumulation as a prostate tumor suppressor is
clearly defined and includes apoptotic as well as other
tumor suppressor effects. We should not preclude the pos-
sibility that, in addition to ZIP1, other zinc transporters
could be involved in the loss of zinc in malignant prostate
cells. Presently, no strong evidence exists that implicates
other zinc transporters in malignant prostate cells in situ
in prostate cancer.
Zinc in the treatment/prevention of prostate cancer: not 
an enigma
The above discussion leads to a rational expectation that
the restoration of zinc accumulation in the malignant
prostate cells should arrest the malignancy and cause the
death of the tumor cells. Moreover, if zinc accumulation
is restored in the neoplastic/premalignant stage (figure 3),
overt malignancy should be prevented. How can these
expectations be achieved? One must begin with the recog-
nition of two requirements for the efficacious employ-
ment of zinc against prostate cancer: 1) the bioavailability
of sufficient zinc (i.e. the interstitial fluid zinc) for uptake
by the prostate cells; and 2) the availability of a cellular
zinc uptake process (e.g. ZIP1). As long as these two
requirements are not compromised by the imposition of
interfering factors or conditions, the clinical and experi-
mental evidence of the tumor-suppressive effects of zinc
should be manifested.
At this point, we cannot ignore the one dot that has not
yet been connected; which is the composite results of epi-
demiologic studies. Several studies that attempt to relate
the use of dietary zinc supplementation to prostate cancer
have been reported. The results and conclusions of these
studies have varied from zinc supplement use having no
effect; zinc supplement use being preventative against
prostate cancer; and zinc supplement having harmful
exacerbating effects on prostate cancer. These studies and
the complex and multivariate factors that impact them are
the subject of our recent review [11]; and will not be
repeated here-in. There is a major concern that must be
highlighted. The epidemiologic studies cannot and
should not be interpreted as evidence that contradicts the
clinically and experimentally established relationships
that we have presented. [for review see [11]]. A clear dis-
tinction must be made between any effects of dietary zinc
supplement use and the direct effects of zinc accumula-
tion on prostate malignancy. The former is complicated
by the interaction of known and unknown variables that
either compromise the bioavailability of zinc and/or the
ability of cells to accumulate zinc. In fact, in the case of
reported adverse effects of use of high zinc supplements,
the possibility exists that factors other than the bioavaila-
bility of zinc are responsible for such effects. There is a
consistency in all the reports that the use of moderate lev-
els of zinc supplement does not impose any additional
risk; and in some reports could be efficacious against pros-
tate cancer. This is important in the elderly male popula-
tion in which the bioavailabilty of zinc and its uptake in
cells tend to decline with aging [reviewed in [11]]. There-
fore, we believe that the prudent use of dietary zinc sup-
plement should be emphasized for this population for
general and prostate health reasons. Most importantly,
the present inconsistencies of the results from epidemio-
logic studies do not alter the clinical and experimental
consistency of the zinc relationship when the conditions
that we described are met. Comparison of zinc levels in normal, benign, and cancer tis- sue Figure 7
Comparison of zinc levels in normal, benign, and cancer tis-
sue. Each point represents a sample from a different subject.Molecular Cancer 2006, 5:17 http://www.molecular-cancer.com/content/5/1/17
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Zinc in the treatment/prevention of prostate cancer: 
potential directions
This provides a basis for consideration of regimens that
can achieve the uptake and accumulation of zinc in neo-
plastic/malignant cells and can provide tumor-suppres-
sive effects against prostate cancer.
a. Genetic manipulation to restore the expression of ZIP1.
Presently this is not a practical approach.
b. Genetic manipulation to "activate" expression of alter-
native zinc uptake transporters. Presently this is not a
practical approach.
c. Eliminate or modify the environment conditions of the
prostate gland that initiate the epigenetic silencing of Zip1
gene expression. This is dependent upon the elucidation
of the mechanism responsible for the down regulation of
ZIP1. Once this issue is resolved, this could be a plausible
approach.
d. Increase the bioavailability of zinc. This has been the
basis for the common use of dietary supplemental zinc as
described above. In the elderly male population, supple-
mental zinc would be efficacious in maintaining a normal
plasma zinc level. This should be incorporated into or
along with any other interventions. It is also possible that
an elevated plasma zinc level could result in zinc uptake
by the malignant cells in the absence of ZIP1. This would
be dependent upon an elevation of plasma low molecular
weight zinc-ligands that become available for cellular
uptake [9,11].
e. Incorporation of agents that will deliver and transport
zinc into the malignant cells. This is based on the use of
ionophores such as sodium pyrithione to deliver cations
into cells. The lack of cation specificity and cell specificity
might impose toxic effects, which would need to be
addressed.
f. Use of m-aconitase inhibitor. A major effect of zinc is its
inhibition of m-aconitase activity and citrate oxidation. In
its absence, an alternative m-aconitase inhibitor could be
employed. Fluoroacetate (→ fluorocitrate) is such an
inhibitor. However it is not cell specific and is toxic to
other mammalian cells. The development of a prostate
cell-specific agent or a cell-specific chaperone for delivery
could provide the inhibitory effect on citrate oxidation in
the malignant cells.
These are some approaches that are based on the zinc rela-
tionships. Additional approaches exist that are based on
other aspects of prostate metabolism. For example, inhi-
bition of lipogenic reactions such as ATP citrate lyase [34]
and AceCS1 provides potential direction. However, in the
case of prostate cancer, more information regarding the
genetic/molecular/metabolic relationships of malignancy
is essential to such future clinical application.
Conclusion
The clinical and experimental evidence leads to the fol-
lowing genetic/metabolic relationships in prostate cancer.
1. The unique function of high citrate production and
secretion by human prostate glands dictates the metabolic
activity and associated genetic requirements of the highly
specialized glandular epithelial cells. The unique accumu-
lation of zinc by these cells is a requirement for the
achievement of this function.
2. The bioenergetic/synthetic, growth/proliferation, and
invasive/migration requirement of malignancy dictates
the metabolic activity and associated genetic requirements
of the malignant cells.
3. The malignant process requires the genetic and meta-
bolic transformation of normal zinc-accumulating citrate-
producing normal cells to citrate-oxidizing malignant
cells that lose the ability to accumulate zinc.
4. The accumulation of zinc exhibits tumor-suppressor
effects that are incompatible with the process and activi-
ties of prostate malignancy.
5. The expression of ZIP1 zinc uptake transporter is
responsible for zinc accumulation in prostate cells. ZIP1 is
down regulated in the malignant cells in situ, which
causes the depletion of zinc and elimination of its tumor-
suppressor effects. Therefore we propose that ZIP1is a
tumor-suppressor gene in prostate cancer.
6. The restoration of high zinc levels in premalignant/
malignant prostate cells will arrest and/or abort prostate
malignancy.
7. These relationships can serve as the basis for new
approaches to the treatment and prevention of prostate
cancer.
8. Genetic/metabolic relationships in prostate malignancy
are beginning to provide an understanding of the onset
and progression of prostate cancer. Much more research
in this critical area is required.
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